The adenosine-receptor axis in chronic pain

Daniela Salvemini, Timothy M. Doyle, Tally M. Largent-Milnes, Todd W Vanderah

Research output: Contribution to journalArticle

Abstract

Chronic pain is a widespread problem that plagues an estimated 10 to 30% of the world’s population. The current therapeutic repertoire is inadequate in managing patient pain with narcotic use resulting in a drug overdose epidemic, affirming the need for the development of new therapeutics. Adenosine and its four cognate receptors (A1AR, A2AAR, A2BAR, and A3AR) play essential roles in physiological and pathophysiological states, including chronic pain. For decades, preclinical and clinical studies have revealed that adenosine and A1AR-and to a lesser extent A2AAR-selective agonists have analgesic properties, yet their therapeutic utility has been limited by adverse cardiovascular side effects. There is no evidence that A2BAR plays a role in pain. Recent preclinical studies have demonstrated that selective A3AR agonists result in antinociception in models of acute and chronic pain while lacking unwanted side effects. These exciting preclinical observations of A3AR agonists have been bolstered by clinical trials of A3AR agonists in other disease states including rheumatoid arthritis and psoriasis that suggests a clinical benefit without cardiotoxicity. Our goal herein is to briefly discuss adenosine and its receptors in the context of pathological pain and examine what is known at present regarding A3AR-mediated antinociception. We will highlight recent findings pertaining to A3AR in pain and describe possible pathways by which A3AR may mediate its effects and the current state of selective A3AR agonists used in pain studies. The adenosine-to-A3AR pathway represents an important endogenous system that can be targeted to provide safe, effective pain relief in patients suffering with chronic pain.

Original languageEnglish (US)
Pages (from-to)413-437
Number of pages25
JournalReceptors
Volume34
DOIs
StatePublished - Jan 1 2018

Fingerprint

Purinergic P1 Receptors
Chronic Pain
Pain
Adenosine
Drug Overdose
Plague
Narcotics
Acute Pain
Psoriasis
Analgesics
Rheumatoid Arthritis
Therapeutics
Clinical Trials
Population

Keywords

  • AAR
  • AAR agonists
  • AAR-mediated antinociception
  • Acute pain
  • Adenosine receptors
  • Chronic pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The adenosine-receptor axis in chronic pain. / Salvemini, Daniela; Doyle, Timothy M.; Largent-Milnes, Tally M.; Vanderah, Todd W.

In: Receptors, Vol. 34, 01.01.2018, p. 413-437.

Research output: Contribution to journalArticle

Salvemini, D, Doyle, TM, Largent-Milnes, TM & Vanderah, TW 2018, 'The adenosine-receptor axis in chronic pain', Receptors, vol. 34, pp. 413-437. https://doi.org/10.1007/978-3-319-90808-3_16
Salvemini, Daniela ; Doyle, Timothy M. ; Largent-Milnes, Tally M. ; Vanderah, Todd W. / The adenosine-receptor axis in chronic pain. In: Receptors. 2018 ; Vol. 34. pp. 413-437.
@article{a745c9a3ffc4487c937adddcafb92d08,
title = "The adenosine-receptor axis in chronic pain",
abstract = "Chronic pain is a widespread problem that plagues an estimated 10 to 30{\%} of the world’s population. The current therapeutic repertoire is inadequate in managing patient pain with narcotic use resulting in a drug overdose epidemic, affirming the need for the development of new therapeutics. Adenosine and its four cognate receptors (A1AR, A2AAR, A2BAR, and A3AR) play essential roles in physiological and pathophysiological states, including chronic pain. For decades, preclinical and clinical studies have revealed that adenosine and A1AR-and to a lesser extent A2AAR-selective agonists have analgesic properties, yet their therapeutic utility has been limited by adverse cardiovascular side effects. There is no evidence that A2BAR plays a role in pain. Recent preclinical studies have demonstrated that selective A3AR agonists result in antinociception in models of acute and chronic pain while lacking unwanted side effects. These exciting preclinical observations of A3AR agonists have been bolstered by clinical trials of A3AR agonists in other disease states including rheumatoid arthritis and psoriasis that suggests a clinical benefit without cardiotoxicity. Our goal herein is to briefly discuss adenosine and its receptors in the context of pathological pain and examine what is known at present regarding A3AR-mediated antinociception. We will highlight recent findings pertaining to A3AR in pain and describe possible pathways by which A3AR may mediate its effects and the current state of selective A3AR agonists used in pain studies. The adenosine-to-A3AR pathway represents an important endogenous system that can be targeted to provide safe, effective pain relief in patients suffering with chronic pain.",
keywords = "AAR, AAR agonists, AAR-mediated antinociception, Acute pain, Adenosine receptors, Chronic pain",
author = "Daniela Salvemini and Doyle, {Timothy M.} and Largent-Milnes, {Tally M.} and Vanderah, {Todd W}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-90808-3_16",
language = "English (US)",
volume = "34",
pages = "413--437",
journal = "Receptors",
issn = "1048-6909",
publisher = "Humana Press",

}

TY - JOUR

T1 - The adenosine-receptor axis in chronic pain

AU - Salvemini, Daniela

AU - Doyle, Timothy M.

AU - Largent-Milnes, Tally M.

AU - Vanderah, Todd W

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Chronic pain is a widespread problem that plagues an estimated 10 to 30% of the world’s population. The current therapeutic repertoire is inadequate in managing patient pain with narcotic use resulting in a drug overdose epidemic, affirming the need for the development of new therapeutics. Adenosine and its four cognate receptors (A1AR, A2AAR, A2BAR, and A3AR) play essential roles in physiological and pathophysiological states, including chronic pain. For decades, preclinical and clinical studies have revealed that adenosine and A1AR-and to a lesser extent A2AAR-selective agonists have analgesic properties, yet their therapeutic utility has been limited by adverse cardiovascular side effects. There is no evidence that A2BAR plays a role in pain. Recent preclinical studies have demonstrated that selective A3AR agonists result in antinociception in models of acute and chronic pain while lacking unwanted side effects. These exciting preclinical observations of A3AR agonists have been bolstered by clinical trials of A3AR agonists in other disease states including rheumatoid arthritis and psoriasis that suggests a clinical benefit without cardiotoxicity. Our goal herein is to briefly discuss adenosine and its receptors in the context of pathological pain and examine what is known at present regarding A3AR-mediated antinociception. We will highlight recent findings pertaining to A3AR in pain and describe possible pathways by which A3AR may mediate its effects and the current state of selective A3AR agonists used in pain studies. The adenosine-to-A3AR pathway represents an important endogenous system that can be targeted to provide safe, effective pain relief in patients suffering with chronic pain.

AB - Chronic pain is a widespread problem that plagues an estimated 10 to 30% of the world’s population. The current therapeutic repertoire is inadequate in managing patient pain with narcotic use resulting in a drug overdose epidemic, affirming the need for the development of new therapeutics. Adenosine and its four cognate receptors (A1AR, A2AAR, A2BAR, and A3AR) play essential roles in physiological and pathophysiological states, including chronic pain. For decades, preclinical and clinical studies have revealed that adenosine and A1AR-and to a lesser extent A2AAR-selective agonists have analgesic properties, yet their therapeutic utility has been limited by adverse cardiovascular side effects. There is no evidence that A2BAR plays a role in pain. Recent preclinical studies have demonstrated that selective A3AR agonists result in antinociception in models of acute and chronic pain while lacking unwanted side effects. These exciting preclinical observations of A3AR agonists have been bolstered by clinical trials of A3AR agonists in other disease states including rheumatoid arthritis and psoriasis that suggests a clinical benefit without cardiotoxicity. Our goal herein is to briefly discuss adenosine and its receptors in the context of pathological pain and examine what is known at present regarding A3AR-mediated antinociception. We will highlight recent findings pertaining to A3AR in pain and describe possible pathways by which A3AR may mediate its effects and the current state of selective A3AR agonists used in pain studies. The adenosine-to-A3AR pathway represents an important endogenous system that can be targeted to provide safe, effective pain relief in patients suffering with chronic pain.

KW - AAR

KW - AAR agonists

KW - AAR-mediated antinociception

KW - Acute pain

KW - Adenosine receptors

KW - Chronic pain

UR - http://www.scopus.com/inward/record.url?scp=85058241427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058241427&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-90808-3_16

DO - 10.1007/978-3-319-90808-3_16

M3 - Article

VL - 34

SP - 413

EP - 437

JO - Receptors

JF - Receptors

SN - 1048-6909

ER -